Ninety patients (63 women and 27 men; mean age, 37 years) suffering from common migraine were treated, according to a double-blind experimental scheme, with a new formulation of slow-release dihydroergotamine (DHE-CP) either 5 mg BID or 10 once daily for two months. The results show the preventive treatment to be effective, with a significant reduction (P <0.01 between times) in the severity and frequency of headache and the associated symptoms, independent of the dosage scheme. Tolerance was also considered to be good in that only 4% of the patients (three patients receiving DHE-CP BID and one patient once daily) had to discontinue treatment due to side effects. The daily dosage of DHE-CP may be administered either in a single dose or twice a day with comparable therapeutic effectiveness and safety.
|Number of pages||11|
|Journal||Current Therapeutic Research|
|Publication status||Published - 1991|
ASJC Scopus subject areas